Literature DB >> 22872693

Raising the bar for market authorisation of new drugs.

Huseyin Naci1, Jonathan Cylus, Sotiris Vandoros, Azusa Sato, Kumar Perampaladas.   

Abstract

Mesh:

Year:  2012        PMID: 22872693     DOI: 10.1136/bmj.e4261

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  7 in total

1.  Relative efficacy and effectiveness assessment of new pharmaceuticals in three EU member states: current practices and outcome agreement between Belgium, the Netherlands and France.

Authors:  P B Van Wilder; V V Bormans; A G Dupont
Journal:  Eur J Clin Pharmacol       Date:  2013-09-01       Impact factor: 2.953

2.  Continual proteomic divergence of HepG2 cells as a consequence of long-term spheroid culture.

Authors:  Andrea Antonio Ellero; Iman van den Bout; Maré Vlok; Allan Duncan Cromarty; Tracey Hurrell
Journal:  Sci Rep       Date:  2021-05-25       Impact factor: 4.379

Review 3.  Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study.

Authors:  Huseyin Naci; John P A Ioannidis
Journal:  Br J Sports Med       Date:  2015-11       Impact factor: 13.800

4.  Identifying market risk for substandard and falsified medicines: an analytic framework based on qualitative research in China, Indonesia, Turkey and Romania.

Authors:  Elizabeth Pisani; Adina-Loredana Nistor; Amalia Hasnida; Koray Parmaksiz; Jingying Xu; Maarten Oliver Kok
Journal:  Wellcome Open Res       Date:  2019-04-16

Review 5.  Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study.

Authors:  Huseyin Naci; John P A Ioannidis
Journal:  BMJ       Date:  2013-10-01

6.  Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.

Authors:  Courtney Davis; Huseyin Naci; Evrim Gurpinar; Elita Poplavska; Ashlyn Pinto; Ajay Aggarwal
Journal:  BMJ       Date:  2017-10-04

7.  Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making.

Authors:  Robbe Saesen; Stéphane Lejeune; Gianluca Quaglio; Denis Lacombe; Isabelle Huys
Journal:  Front Pharmacol       Date:  2020-02-05       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.